{
  "url": "https://openlegislation.uk/eu-directive-2004-33/annex-III/division-2/division-2.1",
  "json_url": "https://openlegislation.uk/eu-directive-2004-33/annex-III/division-2/division-2.1.json",
  "legislation": "eudr/2004/33",
  "legislation_title": "Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-directive-2004-33",
  "path": "annex/III/division/2/division/2.1",
  "kind": "division",
  "number": "2.1",
  "heading": "Permanent deferral criteria for donors of allogeneic donations",
  "text": "Cardiovascular disease\nProspective donors with active or past serious cardiovascular disease, except congenital abnormalities with complete cure\nCentral nervous system disease\nA history of serious CNS disease\nAbnormal bleeding tendency\nProspective donors who give a history of a coagulopathy\nRepeated episodes of syncope, or a history of convulsions\nOther than childhood convulsions or where at least three years have elapsed since the date the donor last took anticonvulsant medication without any recurrence of convulsions\nGastrointestinal, genitourinary, haematological, immunological, metabolic, renal, or respiratory system diseases\nProspective donors with serious active, chronic, or relapsing disease\nDiabetes\nIf being treated with insulin\nInfectious diseases\nHepatitis B, except for HBsAg-negative persons who are demonstrated to be immune\nHepatitis C\nHIV-1/2\nHTLV I/II\nBabesiosis (*)\nKala Azar (visceral leishmaniasis) (*)\nTrypanosomiasis cruzi (Chagas' disease) (*)\nMalignant diseases\nExcept in situ cancer with complete recovery\nTransmissible spongiform encephalopathies (TSEs), (e.g. Creutzfeldt Jakob Disease, variant Creutzfeldt Jakob Disease)\nPersons who have a family history which places them at risk of developing a TSE, or persons who have received a corneal or dura mater graft, or who have been treated in the past with medicines made from human pituitary glands. For variant Creutzfeldt Jacob disease, further precautionary measures may be recommended.\nIntravenous (IV) or intramuscular (IM) drug use\nAny history of non-prescribed IV or IM drug use, including body-building steroids or hormones\nXenotransplant recipients\nSexual behaviour\nPersons whose sexual behaviour puts them at high risk of acquiring severe infectious diseases that can be transmitted by blood",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudr/2004/33/annex/III/division/2/division/2.1",
    "retrieved_at": "2026-11-01T15:22:49.438638+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}